Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients
BYPASS-CTCA
A Randomised Controlled Trial Assessing the Value of Computed Tomography Cardiac Angiography in Improving Patient Satisfaction and Reducing Contrast Load, Procedural Duration and Complications in Patients Who Had Previous Bypass Surgery Undergoing Coronary Angiography
1 other identifier
interventional
688
1 country
2
Brief Summary
A large number of patients with symptomatic ischaemic heart disease undergo coronary artery bypass grafting (CABG) to alleviate their symptoms and improve prognosis. Given the progressive nature of coronary disease, bypass grafts can narrow or block over time, leading to chest pain and the need for further invasive coronary angiography. Invasive coronary procedures in patients with bypass grafts can be more complicated due to the variation in bypass graft ostia. This can lead to longer procedure times, with higher doses of contrast and radiation and more discomfort for the patient. The aim of this study is to see if the use of computed tomography coronary angiography (CTCA) in patients with previous bypass grafts prior to invasive coronary angiography will help make their procedure safer and quicker.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2018
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 14, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2024
CompletedFirst Submitted
Initial submission to the registry
November 4, 2024
CompletedFirst Posted
Study publicly available on registry
June 15, 2025
CompletedJune 15, 2025
June 1, 2025
5.3 years
November 4, 2024
June 6, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Procedural duration
To measure the length of coronary angiographic procedure
timer started after the insertion of the arterial catheter and stopped when the catheters are removed
Incidence of Contrast Induced Nephropathy
Defined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria
48-72 hours
Patient Satisfaction
Patient satisfaction measured by validated questionnaire
4-6 hours post angiogram +/- percutaneous coronary intervention
Secondary Outcomes (8)
Contrast Amount
During procedure
Radiation Exposure
During procedure
Angiography Related Complications
During procedure
Radial Access Rate
During procedure
Catheters Used
During procedure
- +3 more secondary outcomes
Study Arms (2)
CTCA + ICA
ACTIVE COMPARATORComputed Tomography Cardiac Angiography (CTCA) performed prior to invasive coronary angiography (ICA).
ICA only
NO INTERVENTIONInvasive coronary angiography (ICA) performed only.
Interventions
Computed Tomography Coronary Angiography (CTCA) performed prior to invasive coronary angiography (ICA)
Eligibility Criteria
You may qualify if:
- Patients undergoing coronary angiography +/-Percutaneous coronary Intervention
- Previous Coronary Artery Bypass Grafting (CABG)
- Aged ≥18
- Patients able and willing to give their written informed consent.
You may not qualify if:
- Subjects presenting with ST elevation myocardial infarction, cardiogenic shock (systolic blood pressure \<80 mmHg for \>30 minutes, or requiring inotropes or emergency intra aortic balloon pump for hypotension treatment) or cardiopulmonary resuscitation.
- Subjects with eGFR \<20ml/min or on renal replacement therapy.
- Current life-threatening condition other than vascular disease that may prevent a subject completing the study.
- Clinical instability including cardiogenic shock, hypotension (low blood pressure-systolic blood pressure less than 90 mmHg), sustained ventricular or atrial arrhythmia requiring intravenous medications.
- Inability to tolerate beta-blockers, including those with chronic obstructive pulmonary disease or asthma, complete heart block, second-degree atrioventricular block
- Known contrast dye allergy.
- Pregnancy or unknown pregnancy status.
- Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures).
- Inability or refusal to provide informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Royal London Hospital
London, E1 1FR, United Kingdom
St Bartholomew's Hospital
London, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Daniel Jones, MRCP, PhD
Queen Mary University of London
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 4, 2024
First Posted
June 15, 2025
Study Start
November 14, 2018
Primary Completion
February 28, 2024
Study Completion
February 28, 2024
Last Updated
June 15, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- Mid-late 2018
- Access Criteria
- Freely available via journal
The trial protocol will be published